Aug. 21, 2025 — The medical imaging market is projected to have a compound annual growth rate of nearly six percent over the next seven years.


The Digital Imaging and Communications in Medicine (DICOM) standard is the bedrock of interoperability, yet achieving its full potential within complex hospital environments remains a challenge. This is a particular challenge for pathology, where legacy infrastructure means it has the furthest to go to achieve DICOM standardization.

But the clock is ticking. So, let's be realistic. Instead of waiting for the DICOM utopia, we should embrace middleware as a pragmatic solution to quickly bridge the gap between existing systems and modern applications.

Aug. 22, 2025 — Esaote recently announced that the MyLab A50 and MyLab A70 ultrasound systems have received FDA approval. Previously unveiled to the international medical community, these advanced platforms are now cleared for distribution in the United States, underscoring Esaote's ongoing commitment to innovation in diagnostic imaging.

August 18, 2025 – Akumin, a national leader in outpatient radiology and oncology services, has selected Lunit INSIGHT DBT, a leading AI solution for early breast cancer detection. The decision marks a key step in Akumin’s plans to integrate advanced technologies that elevate care delivery and expand patient access to precision diagnostics. 

Aug. 19, 2025 — According to the latest study from BCC Research, the "Global Mammography Equipment Markets" is projected to grow from $3.1 billion in 2025 to $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

This report provides a detailed review of the global mammography equipment market, highlighting current technologies, growth drivers and emerging opportunities. The report segments by equipment type, end-user industry, and region.

Aug. 19, 2025 — Calidar, Inc., a start-up in precision diagnostic imaging formed out of Duke University, recently announced the successful imaging of the first patient with its 4D Mammography system. The next-generation imaging system harnesses X-ray diffraction and AI to measure novel molecular-level signals of disease, offering the potential to significantly improve diagnostic accuracy.

Aug. 12, 2025 — MARS Bioimaging has appointed of Dr. Ojas Mahapatra as Group Chief Executive Officer. Mahapatra is an accomplished executive with more than a decade of experience scaling and transforming deep-tech companies in global markets. Mahapatra most recently was CEO of New Zealand cleantech company Fabrum.

Aug. 13, 2025 — A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. Using data collected nationwide over a period of eight years, researchers confirmed that PSMA PET/CT is a valuable tool for identifying patients who are likely to benefit from salvage radiotherapy. This research was published in the August issue of The Journal of Nuclear Medicine.

Aug. 13, 2025 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, recently announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

Aug. 12, 2025 —Sonic Incytes Medical Corp, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE, its point-of-care ultrasound elastography device. Building on the success of its original model, Velacur, Velacur ONE introduces an enhanced interface and features for improved portability and user experience. These improvements enable broader scalability to support Sonic Incytes’ accelerated US and global expansion strategy.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now